Nicholas Wilcken
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nicholas Wilcken has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Rachel Dear
2 shared publications- Andreas Carus
Department of Oncology and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
1 shared publication Annabel Goodwin
Cancer Genetics, Westmead Hospital, Hawksberry Road, Westmead, NSW, Australia, 2145
1 shared publicationDavina Ghersi
Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia
1 shared publication- Frede Donskov
Department of Oncology, University Hospital of Southern Denmark, Esbjerg, Denmark
1 shared publication - Hans von der Maase
Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
1 shared publication
Latest Publications
- Open Access
- 1 January 2013
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 11 (1) , 189
Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia
Chronic inflammation has been recognized to foster tumour development. Whether chemotherapy can be used to neutralize chronic inflammation is unclear.
- 1 January 2013
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 11 (1) , 189
Open AccessImpact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia
Chronic inflammation has been recognized to foster tumour development. Whether chemotherapy can be used to neutralize chronic inflammation is unclear.
- 7 October 2009
- Published by Wiley
- No. 4,p. CD000563
Post-operative radiotherapy for ductal carcinoma in situ of the breast
Background The addition of radiotherapy (RT) following breast conserving surgery (BCS) was first shown to reduce the risk of ipsilateral recurrence in the treatment of invasive breast cancer. Ductal carcinoma in situ ( DCIS) is a pre-invasive lesion. Recurrence of ipsilateral disease following BCS can be either DCIS or invasive breast cancer. Randomised controlled trials (RCTs) have shown that RT can reduce the risk of recurrence, but assessment of potential long-term complications from addition of RT following BSC for DCIS has not been reported for women participating in RCTs. Objectives To summarise the data from RCTs testing the addition of RT to BCS for treatment of DCIS to determine the balance between the benefits and harms. Search strategy We searched the Cochrane Breast Cancer Group Specialised Register ( January 2008), Cochrane Central Register of Controlled Trials ( CENTRAL) ( The Cochrane Library 2008, Issue 1), MEDLINE ( February 2008), and EMBASE ( February 2008). Reference lists of articles and handsearching of ASCO ( 2007), ESMO ( 2002 to 2007), and St Gallen ( 2005 to 2007) conferences were performed. Selection criteria RCTs of breast conserving surgery with and without radiotherapy in women at first diagnosis of pure ductal carcinoma in situ ( no invasive disease present). Data collection and analysis Two authors independently assessed each potentially eligible trial for inclusion and its quality. Two authors also independently extracted data from published Kaplan-Meier analysis ( survival curves) and reported summary statistics. Data were extracted and pooled for four trials. Data for planned subgroups were extracted and pooled for analysis. There were insufficient data to pool for long-term toxicity from radiotherapy. Main results Four RCTs involving 3925 women were identified and included in this review. All were high quality with minimal risk of bias. Three trials compared the addition of RT to BCS. One trial was a two by two factorial design comparing the use of RT and tamoxifen, each separately or together, in which participants were randomised in at least one arm. Analysis confirmed a statistically significant benefit from the addition of radiotherapy on all ipsilateral breast events (hazards ratio (HR) 0.49; 95% CI 0.41 to 0.58, P < 0.00001), ipsilateral invasive recurrence (HR 0.50; 95% CI 0.32 to 0.76, p=0.001) and ipsilateral DCIS recurrence (HR 0.61; 95% CI 0.39 to 0.95, P=0.03). All the subgroups analysed benefited from addition of radiotherapy. No significant long-term toxicity from radiotherapy was found. No information about short-term toxicity from radiotherapy or quality of life data were reported. Authors' conclusions This review confirms the benefit of adding radiotherapy to breast conserving surgery for the treatment of all women diagnosed with DCIS. No long-term toxicity from use of radiotherapy was identified.
- 7 October 2009
- Published by Wiley
- No. 4,p. CD000563
Post-operative radiotherapy for ductal carcinoma in situ of the breast
Background The addition of radiotherapy (RT) following breast conserving surgery (BCS) was first shown to reduce the risk of ipsilateral recurrence in the treatment of invasive breast cancer. Ductal carcinoma in situ ( DCIS) is a pre-invasive lesion. Recurrence of ipsilateral disease following BCS can be either DCIS or invasive breast cancer. Randomised controlled trials (RCTs) have shown that RT can reduce the risk of recurrence, but assessment of potential long-term complications from addition of RT following BSC for DCIS has not been reported for women participating in RCTs. Objectives To summarise the data from RCTs testing the addition of RT to BCS for treatment of DCIS to determine the balance between the benefits and harms. Search strategy We searched the Cochrane Breast Cancer Group Specialised Register ( January 2008), Cochrane Central Register of Controlled Trials ( CENTRAL) ( The Cochrane Library 2008, Issue 1), MEDLINE ( February 2008), and EMBASE ( February 2008). Reference lists of articles and handsearching of ASCO ( 2007), ESMO ( 2002 to 2007), and St Gallen ( 2005 to 2007) conferences were performed. Selection criteria RCTs of breast conserving surgery with and without radiotherapy in women at first diagnosis of pure ductal carcinoma in situ ( no invasive disease present). Data collection and analysis Two authors independently assessed each potentially eligible trial for inclusion and its quality. Two authors also independently extracted data from published Kaplan-Meier analysis ( survival curves) and reported summary statistics. Data were extracted and pooled for four trials. Data for planned subgroups were extracted and pooled for analysis. There were insufficient data to pool for long-term toxicity from radiotherapy. Main results Four RCTs involving 3925 women were identified and included in this review. All were high quality with minimal risk of bias. Three trials compared the addition of RT to BCS. One trial was a two by two factorial design comparing the use of RT and tamoxifen, each separately or together, in which participants were randomised in at least one arm. Analysis confirmed a statistically significant benefit from the addition of radiotherapy on all ipsilateral breast events (hazards ratio (HR) 0.49; 95% CI 0.41 to 0.58, P < 0.00001), ipsilateral invasive recurrence (HR 0.50; 95% CI 0.32 to 0.76, p=0.001) and ipsilateral DCIS recurrence (HR 0.61; 95% CI 0.39 to 0.95, P=0.03). All the subgroups analysed benefited from addition of radiotherapy. No significant long-term toxicity from radiotherapy was found. No information about short-term toxicity from radiotherapy or quality of life data were reported. Authors' conclusions This review confirms the benefit of adding radiotherapy to breast conserving surgery for the treatment of all women diagnosed with DCIS. No long-term toxicity from use of radiotherapy was identified.
- 31 October 2008
- Published by Elsevier in European Journal of Cancer
- Vol. 44 (15) , 2218-2225
Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000–2007
- 31 October 2008
- Published by Elsevier in European Journal of Cancer
- Vol. 44 (15) , 2218-2225
Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000–2007
- 2 February 2008
- Vol. 37, 45-9
Beyond chemotherapy--demystifying the new 'targeted' cancer treatments.
It has been known for some time that key genetic changes are the principle mechanism of cancer development. These changes lead to abnormalities in the signalling pathways of cells and result in unregulated cell growth, angiogenesis and metastasis.
- 2 February 2008
- Vol. 37, 45-9
Beyond chemotherapy--demystifying the new 'targeted' cancer treatments.
It has been known for some time that key genetic changes are the principle mechanism of cancer development. These changes lead to abnormalities in the signalling pathways of cells and result in unregulated cell growth, angiogenesis and metastasis.
- 1 May 2007
- Published by Elsevier in The Lancet
- Vol. 369 (9574) , 1668-1670
Ovarian suppression for early breast cancer
- 1 May 2007
- Published by Elsevier in The Lancet
- Vol. 369 (9574) , 1668-1670
Ovarian suppression for early breast cancer